The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.
Successfully incorporating AI into future products will fulfil Medtronic’s mission of using biomedical engineering to restore health and reduce the management burden for people with diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback